adplus-dvertising
Connect with us

Business

Trudeau urges Canadians to take first vaccine they're offered, says 'the science is evolving' – National Post

Published

 on


Public health officers across Canada suspended the use of the Astrazeneca vaccine in people under the age of 55 just as 1.5 million doses arrived in the country

Article content

OTTAWA —Just as 1.5 million doses of AstraZeneca’s COVID-19 vaccine arrived in Canada Tuesday new guidelines will restrict the number of people who can take it, but Prime Minister Justin Trudeau urged Canadians to trust the science and accept the first vaccine they are offered.

Public health officers across the country suspended the use of the Astrazeneca vaccine in people under the age of 55 over concerns the vaccine might cause rare, but serious and potentially fatal blood clots. Canada has already received 500,000 doses of the vaccine and a further 1.5 million were on route from the United States on Tuesday.

The American doses are to be sent to provinces this week after a few regulatory hurdles are worked out. A further 1.5 million doses of the vaccine manufactured in India are due before mid-May, and the government has a further 18.5 million doses on order.

The clots have been recorded in only a few dozen patients in Europe, even while millions of doses have been administered, but the evidence suggests younger people are at higher risk of the clots, while at relatively lower risk of getting seriously ill from COVID-19.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Trudeau said he understands Canadians’ confusion, but health officials are being prudent and cautious.

“I understand how challenging this can be for Canadians. The science is evolving as we get more and more data experts are refining and shifting their recommendations,” he said.

  1. People line up at a COVID-19 vaccination centre in London, Ont.

    Canadians much less trusting of AstraZeneca than other COVID-19 vaccines: poll

  2. A vial of the AstraZeneca COVID-19 vaccine

    Provinces suspend AstraZeneca shots for people under 55 after advice from national panel

He stressed Canadians who are eligible for the AstraZeneca vaccine should take it because the risk of COVID-19 is far greater.

“The bottom line for Canadians is the right vaccine for you to take is the very first vaccine that you are offered.”

The evidence on the clots is still scattered, with some studies assessing the risk at one in a million cases, while more recent studies put it at one in 100,000 cases. The United Kingdom has rolled out millions of doses of the vaccine and has had no significant issues with blood clots.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Dr. Menaka Pai, a specialist in blood clotting disorders and associate professor at McMaster University, said the pause is the right call so more research can be collected.

“We are dealing with information that’s coming in fast and furious. We do have reports from the EU that are being constantly updated,” she said. “Even though that risk is rare, these are very serious clots, and we’re in the process of learning more about how to best diagnose and treat them.”

While the clots have been rare, in 40 per cent of cases they have been fatal and Pai said that has to scrutinized.

“They’re causing not just blood clots, but very aggressive blood clots, blood clots in unusual locations.”

The change in AstraZeneca’s use came from three separate government agencies on Monday.

Health Canada demanded the company pull more data on these potential clots in Canada broken down by age, but did not change the vaccine’s authorization to limit age groups. The National Advisory Council on Immunization (NACI) recommended it be excluded for people under 55 and provincial public health officers acting as a group decided to follow that advice.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

This is the second change to AstraZeneca’s use: NACI initially suggested it should not be used in seniors because of a lack of data. NACI later reversed that decision when more information came in.

Dr. Theresa Tam, Canada’s chief public health officer, said as confusing as it might be, each part of the vaccine process is important.

“I think you’ve seen that at play (Monday) to take the precautionary approach to keep Canadians as safe as possible while offering a safe and effective vaccine,” she said.

Dr. Zain Chagla, an infectious disease expert at McMaster University, said the one in 100,000 risk might seem remote, but that’s a broad sampling with all age groups involved. Most of the people who have experienced the clots have been younger women and Chagla said given there are other vaccines it makes sense to be cautious.

“We know we seem to have a population that seems to be at higher risk where we could offer them an alternative,” he said.

The bottom line for Canadians is the right vaccine for you to take is the very first vaccine that you are offered

On alternatives, Trudeau announced that Pfizer had agreed to move up five million doses of its vaccine, originally scheduled for later this summer into the first quarter, which would see the country have nearly 40 million doses before Canada Day, not including the AstraZeneca doses that are still arriving.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

In addition to that total, Procurement Minister Anita Anand said Tuesday she expects the first shipments of 10 million Johnson and Johnson vaccines to arrive in April. The J&J vaccine is easier to store and requires only one dose.

Chagla said more data will likely be available in just a few weeks and it will help clarify the risk of the vaccine, but he said the government will have a difficult time changing minds now on the vaccine, especially with two candidates in Pfizer and Moderna that are effective.

“I do think we’re probably not going to use all 20 million doses of the AstraZeneca vaccine because I think there’s just so much hesitancy now built in,” he said.

• Email: rtumilty@postmedia.com | Twitter:

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending